查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2147155

不孕症藥物市場規模、佔有率、成長率、全球產業分析、區域趨勢及2026年至2034年預測。

Fertility Drugs Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

不孕症治療藥物市場的成長要素

2025年全球不孕症治療市場價值為30.5億美元，預計將從2026年的32.4億美元成長到2034年的52.5億美元，在2026年至2034年的預測期內，複合年成長率為6.22%。 2025年，北美以34.1%的市佔率領先，該地區的市場規模約為10.4億美元。

不孕症藥物是用於調節生殖激素、促進排卵、支持卵泡和卵子發育以及改善輔助生殖技術（如體外受精 (IVF) 和人工授精 (IUI)）治療效果的藥物。它們廣泛用於治療排卵障礙、不明原因不孕、卵巢症候群、卵巢儲備功能下降、控制性卵巢刺激。不孕症發病率上升、生育年齡偏大、公眾意識增強以及生育診所的普及正在推動市場成長。

不孕症治療藥物市場趨勢

人們越來越意識到早期診斷和治療不孕症的重要性。

隨著人們對不孕症作為一種常見生殖健康問題的認知不斷提高，越來越多的患者尋求診斷和治療。促排卵療法、促性腺激素分泌、荷爾蒙療法和黃體期維持藥物的廣泛應用，也推動了相關產品的需求成長。

擴大不孕症治療的福利和降低治療成本也是一大趨勢。政府措施、雇主提供的醫療保健福利以及藥物取得計畫都在幫助降低藥物成本，並改善病患獲得治療的機會。

市場促進因素

生育年齡延遲和高齡生產增加是推動需求成長的原因。

生育年齡的上升是推動市場成長的主要因素，越來越多的人因為教育、事業、經濟狀況以及家庭價值觀的轉變而推遲生育。隨著自然生育能力隨年齡成長而下降，對促排卵、控制性卵巢刺激、體外受精（IVF）和人工授精（IUI）等輔助生殖技術的需求日益成長。

輔助生殖技術 (ART) 手術數量的增加、生育治療診所網路的擴張以及藥物研發管線的持續發展也促進了市場成長。

市場限制因素

荷爾蒙刺激療法有安全隱患，限制了其廣泛應用。

不孕症藥物，特別是用於卵巢刺激的促性腺激素分泌，可能會引起卵巢過度刺激症候群等副作用。鑑於這些風險，必須對患者進行嚴密監測，並由專科醫生進行監督。

自付費用高、保險報銷不均以及獲得專業生殖保健服務的機會有限，可能會進一步限制該技術的普及，尤其是在開發中國家市場。

市場機遇

雇主和保險公司提供的不孕症治療福利創造了機會。

擴大雇主和保險公司對不孕症治療的保險覆蓋範圍具有巨大的成長潛力。降低藥物自付費用將激勵患者開始並堅持不孕症治療。

此外，擴大保險報銷範圍可能會促進與體外受精 (IVF) 相關的不孕症藥物的使用，這可能為製藥公司、藥房和不孕症治療提供者創造商機。

市場挑戰

治療成功率的不確定性仍是一大挑戰。不孕症治療並不能保證懷孕或分娩，有些患者可能需要多個治療週期。重複治療會導致藥物費用增加、情緒壓力增加以及治療疲勞，可能導致患者延遲或停止治療。

細分分析

依藥物類別分類，促性腺激素分泌（在控制性卵巢刺激中發揮核心作用）佔據市場主導地位。 「其他」類別預計將以 8.04% 的複合年成長率成長。

按藥物類型分類，由於卵泡刺激素（FSH）在卵泡發育和體外受精（IVF）方案中的廣泛應用，預計到2025年，FSH將佔據最大的市場佔有率。西曲瑞克（Cetrorelix）預計將以9.47%的複合年成長率成長。

就治療方法而言，輔助生殖技術/體外受精（ART/IVF）週期支​​持佔據市場主導地位，因為不孕症治療的每個階段都需要使用藥物：卵巢刺激、促排卵、取卵準備和黃體期維持。男性不孕症治療預計將以6.86%的複合年成長率成長。

就給藥途徑而言，注射劑型佔主導地位，這得益於其能夠精準給藥以及促性腺激素分泌和促排卵藥物的廣泛應用。 「其他」細分市場預計將以10.48%的複合年成長率成長。

按最終用戶分類，不孕症治療診所在 2025 年推動了市場成長，但預計專科診所的複合年成長率將達到 7.01%。

區域展望

預計北美將在2025年以10.4億美元的銷售額佔據榜首。美國市場預計在2026年達到10.3億美元，約佔全球銷售額的31.71%。

預計2026年，歐洲市場規模將達到8.7億美元，年複合成長率為5.27%。其中，德國和英國預計將分別達到2億美元和1.8億美元。

預計到 2026 年，亞太地區的經濟規模將達到 8.9 億美元。其中，中國、日本和印度的經濟規模預計將分別達到約 2.7 億美元、1.9 億美元和 1.2 億美元。

預計到2026年，拉丁美洲的生育藥物市場規模將達到1,900萬美元，而海灣合作理事會（GCC）地區的生育藥物市場規模估計為700萬美元。南非預計將達到約200萬美元。

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢
  • 市場挑戰

第4章：主要考慮因素

  • 主要地區和國家主要不孕症盛行率
  • 管道分析：按主要公司分類
  • 主要地區和國家的監管趨勢概述
  • 新產品發布：按主要公司分類
  • 產業重大發展動態（合併、收購、合作、新產品和服務的推出等）

第5章：2021-2034年全球不孕症治療市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物類別分類
    • 促排卵藥物
    • 促性腺激素分泌
    • 基於hCG的觸發劑
    • GnRH促效劑
    • GnRH拮抗劑
    • 黃體素/黃體期支持藥物
    • 其他
  • 市場分析、洞察與預測：按藥物分類
    • 枸櫞酸氯米芬
    • 來曲唑
    • FSH
    • hMG
    • hCG
    • 孕酮
    • 塞托雷克斯
    • 加尼瑞克斯
    • Leuprorelin acetate
    • 曲普瑞林
    • 其他
  • 市場分析、洞察與預測：按治療方法
    • 輔助生殖技術/體外受精週期支持
    • 除了輔助生殖技術之外，其他女性不孕症治療方法
    • 男性不孕症治療
  • 市場分析、洞察與預測：按給藥途徑
    • 注射藥物
    • 口服
    • 陰道內給藥
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 不孕症治療診所
    • 醫院
    • 專科診所
    • 居家照護/自我管理環境
    • 其他
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美不孕症藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲不孕症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區不孕症藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章：拉丁美洲不孕症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：2021-2034年中東和非洲不孕症治療市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Merck KGaA
    • Ferring BV
    • Organon & Co.
    • IBSA Institut Biochimique SA
    • Gedeon Richter Plc.
    • Theramex
    • Livzon Pharmaceutical Group
    • LG Chem
    • Bharat Serums and Vaccines
    • Lupin Limited.
Product Code: FBI118300

Growth Factors of fertility drugs Market

The global fertility drugs market size was valued at USD 3.05 billion in 2025 and is projected to grow from USD 3.24 billion in 2026 to USD 5.25 billion by 2034, exhibiting a CAGR of 6.22% during the 2026-2034 forecast period. North America dominated the market with a 34.1% share in 2025, representing a regional market value of approximately USD 1.04 billion.

Fertility drugs are medicines used to regulate reproductive hormones, stimulate ovulation, support follicle and egg development, and improve outcomes in assisted reproductive procedures such as IVF and IUI. They are widely used for ovulatory disorders, unexplained infertility, polycystic ovary syndrome, diminished ovarian reserve, and controlled ovarian stimulation. Rising infertility prevalence, delayed parenthood, growing awareness, and wider access to fertility clinics are supporting market expansion.

Fertility Drugs Market Trends

Early Infertility Diagnosis and Treatment Awareness Gain Importance

Growing awareness of infertility as a common reproductive health condition is encouraging more patients to seek diagnosis and treatment. Increasing use of ovulation induction therapies, gonadotropins, hormonal treatments, and luteal phase support medicines is strengthening product demand.

The expansion of fertility benefits and affordability programs is another important trend. Government initiatives, employer-supported healthcare benefits, and pharmaceutical access programs are helping reduce medication costs and improve treatment availability.

Market Drivers

Delayed Parenthood and Rising Maternal Age Drive Demand

Increasing maternal age is a major market driver as more individuals postpone parenthood due to education, careers, economic considerations, and changing family preferences. As fertility naturally declines with age, demand is rising for ovulation induction, controlled ovarian stimulation, IVF, and IUI treatments.

Growing ART procedure volumes, expanding fertility clinic networks, and continued drug pipeline development are also contributing to market growth.

Market Restraints

Safety Concerns Associated with Hormonal Stimulation Limit Adoption

Fertility medicines, particularly gonadotropins used during ovarian stimulation, can cause adverse effects such as ovarian hyperstimulation syndrome. These risks require careful patient monitoring and specialist supervision.

High out-of-pocket costs, uneven reimbursement, and limited access to specialist reproductive healthcare may further restrict adoption, particularly in developing markets.

Market Opportunities

Employer and Insurance Fertility Benefits Create Opportunities

Expansion of fertility coverage through employers and insurers presents significant growth potential. Reduced out-of-pocket medication expenses can encourage patients to begin and continue fertility treatment.

Greater reimbursement support can also increase utilization of IVF-related fertility drugs, creating opportunities for manufacturers, pharmacies, and fertility care providers.

Market Challenges

Uncertain treatment success remains a major challenge. Fertility treatments do not guarantee pregnancy or live birth, and some patients require multiple cycles. Repeated treatment increases medication costs, emotional stress, and treatment fatigue, which may cause patients to delay or discontinue therapy.

Segmentation Analysis

By drug class, gonadotropins dominate due to their central role in controlled ovarian stimulation. The others category is projected to grow at an 8.04% CAGR.

By drug, FSH held the largest market share in 2025 because of its extensive use in follicle development and IVF protocols. Cetrorelix is projected to grow at a 9.47% CAGR.

By treatment, ART/IVF cycle support dominates as fertility medicines are required across ovarian stimulation, ovulation triggering, egg retrieval preparation, and luteal support. Male fertility treatment is projected to grow at a 6.86% CAGR.

By route of administration, injectable drugs dominate due to precise dosing and widespread use of gonadotropins and trigger medicines. The others segment is projected to grow at a 10.48% CAGR.

By end user, fertility clinics led the market in 2025, while specialty clinics are projected to expand at a 7.01% CAGR.

Regional Outlook

North America led with USD 1.04 billion in 2025. The U.S. market is estimated to reach USD 1.03 billion in 2026, representing approximately 31.71% of global revenues.

Europe is projected to reach USD 0.87 billion in 2026 and grow at a 5.27% CAGR. Germany and the U.K. are estimated at USD 0.20 billion and USD 0.18 billion, respectively.

Asia Pacific is expected to reach USD 0.89 billion in 2026. China, Japan, and India are projected at approximately USD 0.27 billion, USD 0.19 billion, and USD 0.12 billion, respectively.

Latin America is projected to reach USD 0.19 billion in 2026, while the GCC fertility drugs market is estimated at USD 0.07 billion. South Africa is projected at approximately USD 0.02 billion.

Competitive Landscape

Major companies include Merck KGaA, Ferring B.V., Organon & Co., IBSA Institut Biochimique SA, Gedeon Richter, Theramex, Livzon Pharmaceutical Group, LG Chem, Bharat Serums and Vaccines, and Lupin Limited. Competition centers on injectable fertility therapies, biosimilars, regulatory approvals, product pipelines, affordability initiatives, and geographic expansion.

Key Industry Developments

In February 2026, EMD Serono expanded access pathways for its IVF medicines, including Gonal-f, Ovidrel, and Cetrotide, in the U.S. In 2025, Ferring advanced follitropin delta research, Organon expanded its fertility manufacturing presence, and Gedeon Richter collaborated with Granata Bio on recombinant FSH development.

Conclusion

The fertility drugs market is expected to maintain steady growth as delayed parenthood, infertility awareness, ART adoption, and fertility clinic expansion increase worldwide. The market is projected to rise from USD 3.05 billion in 2025 to USD 3.24 billion in 2026 and reach USD 5.25 billion by 2034, growing at a 6.22% CAGR. Broader fertility benefits, improved treatment access, drug innovation, and rising IVF utilization will remain the major factors shaping market growth through 2034.

Segmentation By Drug Class, Drug, Treatment, Route of Administration, End User, and Region

By Drug Class

  • Ovulation Induction Agents
  • Gonadotropins
  • hCG-based Trigger Drugs
  • GnRH Agonists
  • GnRH Antagonists
  • Progesterone/Luteal Phase Support Drugs
  • Others

By Drug

  • Clomiphene Citrate
  • Letrozole
  • FSH
  • hMG
  • hCG
  • Progesterone
  • Cetrorelix
  • Ganirelix
  • Leuprolide
  • Triptorelin
  • Others

By Treatment

  • ART/IVF Cycle Support
  • Non-ART Female Fertility Treatment
  • Male Fertility Treatment

By Route of Administration

  • Injectable
  • Oral
  • Vaginal
  • Others

By End User

  • Fertility Clinics
  • Hospitals
  • Specialty Clinics
  • Homecare/Self-administration Settings
  • Others

By Region

  • North America (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Drug, Treatment, Route of Administration, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends
  • 3.5. Market Challenges

4. Key Insights

  • 4.1. Prevalence of Key Fertility Disorders, By Key Regions, Countries
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Overview of Regulatory Scenario, By Key Regions/Countries
  • 4.4. New Product Launches, By Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Ovulation Induction Agents
    • 5.1.2. Gonadotropins
    • 5.1.3. hCG-based Trigger Drugs
    • 5.1.4. GnRH Agonists
    • 5.1.5. GnRH Antagonists
    • 5.1.6. Progesterone/Luteal Phase Support Drugs
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Drug
    • 5.2.1. Clomiphene Citrate
    • 5.2.2. Letrozole
    • 5.2.3. FSH
    • 5.2.4. hMG
    • 5.2.5. hCG
    • 5.2.6. Progesterone
    • 5.2.7. Cetrorelix
    • 5.2.8. Ganirelix
    • 5.2.9. Leuprolide
    • 5.2.10. Triptorelin
    • 5.2.11. Others
  • 5.3. Market Analysis, Insights and Forecast - By Treatment
    • 5.3.1. ART/IVF Cycle Support
    • 5.3.2. Non-ART Female Fertility Treatment
    • 5.3.3. Male Fertility Treatment
  • 5.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.4.1. Injectable
    • 5.4.2. Oral
    • 5.4.3. Vaginal
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By End User
    • 5.5.1. Fertility Clinics
    • 5.5.2. Hospitals
    • 5.5.3. Specialty Clinics
    • 5.5.4. Homecare/Self-administration Settings
    • 5.5.5. Others
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Ovulation Induction Agents
    • 6.1.2. Gonadotropins
    • 6.1.3. hCG-based Trigger Drugs
    • 6.1.4. GnRH Agonists
    • 6.1.5. GnRH Antagonists
    • 6.1.6. Progesterone/Luteal Phase Support Drugs
    • 6.1.7. Others s
  • 6.2. Market Analysis, Insights and Forecast - By Drug
    • 6.2.1. Clomiphene Citrate
    • 6.2.2. Letrozole
    • 6.2.3. FSH
    • 6.2.4. hMG
    • 6.2.5. hCG
    • 6.2.6. Progesterone
    • 6.2.7. Cetrorelix
    • 6.2.8. Ganirelix
    • 6.2.9. Leuprolide
    • 6.2.10. Triptorelin
    • 6.2.11. Others
  • 6.3. Market Analysis, Insights and Forecast - By Treatment
    • 6.3.1. ART/IVF Cycle Support
    • 6.3.2. Non-ART Female Fertility Treatment
    • 6.3.3. Male Fertility Treatment
  • 6.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.4.1. Injectable
    • 6.4.2. Oral
    • 6.4.3. Vaginal
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By End User
    • 6.5.1. Fertility Clinics
    • 6.5.2. Hospitals
    • 6.5.3. Specialty Clinics
    • 6.5.4. Homecare/Self-administration Settings
    • 6.5.5. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Ovulation Induction Agents
    • 7.1.2. Gonadotropins
    • 7.1.3. hCG-based Trigger Drugs
    • 7.1.4. GnRH Agonists
    • 7.1.5. GnRH Antagonists
    • 7.1.6. Progesterone/Luteal Phase Support Drugs
    • 7.1.7. Others s
  • 7.2. Market Analysis, Insights and Forecast - By Drug
    • 7.2.1. Clomiphene Citrate
    • 7.2.2. Letrozole
    • 7.2.3. FSH
    • 7.2.4. hMG
    • 7.2.5. hCG
    • 7.2.6. Progesterone
    • 7.2.7. Cetrorelix
    • 7.2.8. Ganirelix
    • 7.2.9. Leuprolide
    • 7.2.10. Triptorelin
    • 7.2.11. Others
  • 7.3. Market Analysis, Insights and Forecast - By Treatment
    • 7.3.1. ART/IVF Cycle Support
    • 7.3.2. Non-ART Female Fertility Treatment
    • 7.3.3. Male Fertility Treatment
  • 7.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.4.1. Injectable
    • 7.4.2. Oral
    • 7.4.3. Vaginal
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By End User
    • 7.5.1. Fertility Clinics
    • 7.5.2. Hospitals
    • 7.5.3. Specialty Clinics
    • 7.5.4. Homecare/Self-administration Settings
    • 7.5.5. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Ovulation Induction Agents
    • 8.1.2. Gonadotropins
    • 8.1.3. hCG-based Trigger Drugs
    • 8.1.4. GnRH Agonists
    • 8.1.5. GnRH Antagonists
    • 8.1.6. Progesterone/Luteal Phase Support Drugs
    • 8.1.7. Others s
  • 8.2. Market Analysis, Insights and Forecast - By Drug
    • 8.2.1. Clomiphene Citrate
    • 8.2.2. Letrozole
    • 8.2.3. FSH
    • 8.2.4. hMG
    • 8.2.5. hCG
    • 8.2.6. Progesterone
    • 8.2.7. Cetrorelix
    • 8.2.8. Ganirelix
    • 8.2.9. Leuprolide
    • 8.2.10. Triptorelin
    • 8.2.11. Others
  • 8.3. Market Analysis, Insights and Forecast - By Treatment
    • 8.3.1. ART/IVF Cycle Support
    • 8.3.2. Non-ART Female Fertility Treatment
    • 8.3.3. Male Fertility Treatment
  • 8.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.4.1. Injectable
    • 8.4.2. Oral
    • 8.4.3. Vaginal
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By End User
    • 8.5.1. Fertility Clinics
    • 8.5.2. Hospitals
    • 8.5.3. Specialty Clinics
    • 8.5.4. Homecare/Self-administration Settings
    • 8.5.5. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Southeast Asia
    • 8.6.5. Australia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Ovulation Induction Agents
    • 9.1.2. Gonadotropins
    • 9.1.3. hCG-based Trigger Drugs
    • 9.1.4. GnRH Agonists
    • 9.1.5. GnRH Antagonists
    • 9.1.6. Progesterone/Luteal Phase Support Drugs
    • 9.1.7. Others s
  • 9.2. Market Analysis, Insights and Forecast - By Drug
    • 9.2.1. Clomiphene Citrate
    • 9.2.2. Letrozole
    • 9.2.3. FSH
    • 9.2.4. hMG
    • 9.2.5. hCG
    • 9.2.6. Progesterone
    • 9.2.7. Cetrorelix
    • 9.2.8. Ganirelix
    • 9.2.9. Leuprolide
    • 9.2.10. Triptorelin
    • 9.2.11. Others
  • 9.3. Market Analysis, Insights and Forecast - By Treatment
    • 9.3.1. ART/IVF Cycle Support
    • 9.3.2. Non-ART Female Fertility Treatment
    • 9.3.3. Male Fertility Treatment
  • 9.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.4.1. Injectable
    • 9.4.2. Oral
    • 9.4.3. Vaginal
    • 9.4.4. Others
  • 9.5. Market Analysis, Insights and Forecast - By End User
    • 9.5.1. Fertility Clinics
    • 9.5.2. Hospitals
    • 9.5.3. Specialty Clinics
    • 9.5.4. Homecare/Self-administration Settings
    • 9.5.5. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Fertility Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Ovulation Induction Agents
    • 10.1.2. Gonadotropins
    • 10.1.3. hCG-based Trigger Drugs
    • 10.1.4. GnRH Agonists
    • 10.1.5. GnRH Antagonists
    • 10.1.6. Progesterone/Luteal Phase Support Drugs
    • 10.1.7. Others s
  • 10.2. Market Analysis, Insights and Forecast - By Drug
    • 10.2.1. Clomiphene Citrate
    • 10.2.2. Letrozole
    • 10.2.3. FSH
    • 10.2.4. hMG
    • 10.2.5. hCG
    • 10.2.6. Progesterone
    • 10.2.7. Cetrorelix
    • 10.2.8. Ganirelix
    • 10.2.9. Leuprolide
    • 10.2.10. Triptorelin
    • 10.2.11. Others
  • 10.3. Market Analysis, Insights and Forecast - By Treatment
    • 10.3.1. ART/IVF Cycle Support
    • 10.3.2. Non-ART Female Fertility Treatment
    • 10.3.3. Male Fertility Treatment
  • 10.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.4.1. Injectable
    • 10.4.2. Oral
    • 10.4.3. Vaginal
    • 10.4.4. Others
  • 10.5. Market Analysis, Insights and Forecast - By End User
    • 10.5.1. Fertility Clinics
    • 10.5.2. Hospitals
    • 10.5.3. Specialty Clinics
    • 10.5.4. Homecare/Self-administration Settings
    • 10.5.5. Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Merck KGaA
    • 11.2.2. Ferring B.V.
    • 11.2.3. Organon & Co.
    • 11.2.4. IBSA Institut Biochimique SA
    • 11.2.5. Gedeon Richter Plc.
    • 11.2.6. Theramex
    • 11.2.7. Livzon Pharmaceutical Group
    • 11.2.8. LG Chem
    • 11.2.9. Bharat Serums and Vaccines
    • 11.2.10. Lupin Limited.

List of Tables

  • Table 1: Global Fertility Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Fertility Drugs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 3: Global Fertility Drugs Market Revenue (USD billion) Forecast, by Treatment, 2021-2034
  • Table 4: Global Fertility Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 5: Global Fertility Drugs Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 6: Global Fertility Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Fertility Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 8: North America Fertility Drugs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 9: North America Fertility Drugs Market Revenue (USD billion) Forecast, by Treatment, 2021-2034
  • Table 10: North America Fertility Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 11: North America Fertility Drugs Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 12: North America Fertility Drugs Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 13: Europe Fertility Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 14: Europe Fertility Drugs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 15: Europe Fertility Drugs Market Revenue (USD billion) Forecast, by Treatment, 2021-2034
  • Table 16: Europe Fertility Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 17: Europe Fertility Drugs Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 18: Europe Fertility Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific Fertility Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 20: Asia Pacific Fertility Drugs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 21: Asia Pacific Fertility Drugs Market Revenue (USD billion) Forecast, by Treatment, 2021-2034
  • Table 22: Asia Pacific Fertility Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Asia Pacific Fertility Drugs Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 24: Asia Pacific Fertility Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 25: Latin America Fertility Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 26: Latin America Fertility Drugs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 27: Latin America Fertility Drugs Market Revenue (USD billion) Forecast, by Treatment, 2021-2034
  • Table 28: Latin America Fertility Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 29: Latin America Fertility Drugs Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 30: Latin America Fertility Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Fertility Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 32: Middle East & Africa Fertility Drugs Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 33: Middle East & Africa Fertility Drugs Market Revenue (USD billion) Forecast, by Treatment, 2021-2034
  • Table 34: Middle East & Africa Fertility Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 35: Middle East & Africa Fertility Drugs Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 36: Middle East & Africa Fertility Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Fertility Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Fertility Drugs Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Fertility Drugs Market Value Share (%), by Drug, 2025 & 2034
  • Figure 4: Global Fertility Drugs Market Value Share (%), by Treatment, 2025 & 2034
  • Figure 5: Global Fertility Drugs Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 6: Global Fertility Drugs Market Value Share (%), by End User, 2025 & 2034
  • Figure 7: Global Fertility Drugs Market Value Share (%), by Region, 2025 & 2034
  • Figure 8: North America Fertility Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 9: North America Fertility Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 10: North America Fertility Drugs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 11: North America Fertility Drugs Market Value Share (%), by Drug, 2025
  • Figure 12: North America Fertility Drugs Market Value (USD billion), by Treatment, 2025 & 2034
  • Figure 13: North America Fertility Drugs Market Value Share (%), by Treatment, 2025
  • Figure 14: North America Fertility Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 15: North America Fertility Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 16: North America Fertility Drugs Market Value (USD billion), by End User, 2025 & 2034
  • Figure 17: North America Fertility Drugs Market Value Share (%), by End User, 2025
  • Figure 18: North America Fertility Drugs Market Value (USD billion), by Country, 2025 & 2034
  • Figure 19: North America Fertility Drugs Market Value Share (%), by Country, 2025
  • Figure 20: Europe Fertility Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 21: Europe Fertility Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 22: Europe Fertility Drugs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 23: Europe Fertility Drugs Market Value Share (%), by Drug, 2025
  • Figure 24: Europe Fertility Drugs Market Value (USD billion), by Treatment, 2025 & 2034
  • Figure 25: Europe Fertility Drugs Market Value Share (%), by Treatment, 2025
  • Figure 26: Europe Fertility Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 27: Europe Fertility Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 28: Europe Fertility Drugs Market Value (USD billion), by End User, 2025 & 2034
  • Figure 29: Europe Fertility Drugs Market Value Share (%), by End User, 2025
  • Figure 30: Europe Fertility Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Fertility Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Fertility Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 33: Asia Pacific Fertility Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 34: Asia Pacific Fertility Drugs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 35: Asia Pacific Fertility Drugs Market Value Share (%), by Drug, 2025
  • Figure 36: Asia Pacific Fertility Drugs Market Value (USD billion), by Treatment, 2025 & 2034
  • Figure 37: Asia Pacific Fertility Drugs Market Value Share (%), by Treatment, 2025
  • Figure 38: Asia Pacific Fertility Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 39: Asia Pacific Fertility Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 40: Asia Pacific Fertility Drugs Market Value (USD billion), by End User, 2025 & 2034
  • Figure 41: Asia Pacific Fertility Drugs Market Value Share (%), by End User, 2025
  • Figure 42: Asia Pacific Fertility Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Fertility Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 44: Latin America Fertility Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 45: Latin America Fertility Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 46: Latin America Fertility Drugs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 47: Latin America Fertility Drugs Market Value Share (%), by Drug, 2025
  • Figure 48: Latin America Fertility Drugs Market Value (USD billion), by Treatment, 2025 & 2034
  • Figure 49: Latin America Fertility Drugs Market Value Share (%), by Treatment, 2025
  • Figure 50: Latin America Fertility Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 51: Latin America Fertility Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 52: Latin America Fertility Drugs Market Value (USD billion), by End User, 2025 & 2034
  • Figure 53: Latin America Fertility Drugs Market Value Share (%), by End User, 2025
  • Figure 54: Latin America Fertility Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Fertility Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Fertility Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 57: Middle East & Africa Fertility Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 58: Middle East & Africa Fertility Drugs Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 59: Middle East & Africa Fertility Drugs Market Value Share (%), by Drug, 2025
  • Figure 60: Middle East & Africa Fertility Drugs Market Value (USD billion), by Treatment, 2025 & 2034
  • Figure 61: Middle East & Africa Fertility Drugs Market Value Share (%), by Treatment, 2025
  • Figure 62: Middle East & Africa Fertility Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 63: Middle East & Africa Fertility Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 64: Middle East & Africa Fertility Drugs Market Value (USD billion), by End User, 2025 & 2034
  • Figure 65: Middle East & Africa Fertility Drugs Market Value Share (%), by End User, 2025
  • Figure 66: Middle East & Africa Fertility Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Fertility Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 68: Global Fertility Drugs Market Share (%), by Company, 2025